Latest International AIDS Vaccine Initiative Stories
ATLANTA, March 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company focused on development of HIV/AIDS vaccines, today announced its financial results for the fourth quarter and year ended December 31, 2009. GeoVax reported a net loss of $843,275 for the fourth quarter ended December 31, 2009, as compared to a net loss of $1,039,217 for the comparable period in 2008. For the full year of 2009, the Company reported a net loss of...
ATLANTA, Feb. 2 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., president and chief executive officer, will present a corporate update at the 12th Annual BIO CEO & Investor Conference. The presentation will take place at 1:00 p.m. Eastern Time on...
ATLANTA, Jan. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced the appointment of Mark J. Newman, Ph.D. as vice president, research and development. Dr. Newman will be responsible for developing GeoVax's therapeutic HIV vaccine initiative and broadening the GeoVax pipeline. "We...
Researchers from Thomas Jefferson University are one step closer to developing a vaccine against the AIDS disease.Led by Matthias J. Schnell, Ph.D., director of the Jefferson Vaccine Center, the researchers found that a rabies virus"“based vaccine administered to monkeys protected against the simian equivalent of the HIV virus (SIV). The data were published in the journal Vaccine.The researchers previously showed that a rabies-based vaccine expressing HIV and SIV antigens protective against...
ATLANTA, Dec. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its support for World AIDS Day. "Today is the 21st World AIDS Day and as we remember the millions that have lost their fight with the HIV/AIDS pandemic, we remain focused and devoted to commercializing both...
HARRISBURG, Pa., Nov. 30 /PRNewswire-USNewswire/ -- In recognition of World AIDS Day on Dec. 1, Department of Health Secretary Everette James today reminded Pennsylvanians to be tested regularly for HIV - the virus that causes AIDS. "Getting tested is the only way to know your health status and knowing your status is the only way to ensure you receive proper treatment," said James. "We are working to educate the public and ensure that prevention, testing, treatment and counseling services...
SEATTLE, Nov. 30 /PRNewswire/ -- Ken Stuart, Ph.D., president and founder of Seattle Biomedical Research Institute, has been selected to present at the inaugural Partnering for Cures Conference in New York City, Dec. 1-3. Convened by FasterCures, the Washington, D.C.-based center of the Milken Institute, the conference will bring together hundreds of medical research leaders, investors and decision-makers to explore innovative new approaches to pursuing high-risk, long-term investments that...
ATLANTA, Nov. 17 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S. Food and Drug Administration (FDA) has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for GeoVax's therapeutic vaccine as a treatment for...
MIT economist Jeffrey Harris argues that while the scientific obstacles to creating an HIV vaccine are great, the lack of commercial incentive poses a major problem. In his paper, "Why We Don't Have an HIV Vaccine, and How We Can Develop One," published in the November/December issue of the journal Health Affairs, Harris writes that "the recent history of attempts to develop an HIV vaccine represents a textbook case in the economics of inadequate private incentives."Given the recent...
ROCKVILLE, Md., Oct. 21 /PRNewswire-USNewswire/ -- The U.S. Military HIV Research Program (MHRP), in coordination with the Rockville Vaccine Assessment Clinic (RVAC), is holding an informational event about HIV vaccine research on Thursday, October 29, 2009 from 6:00-7:30 p.m. at 1600 E. Gude Drive, Rockville MD 20850. The event will feature a guest speaker from MHRP who will discuss HIV vaccine trials as well as a community stakeholder speaking about their experience. MHRP hopes to engage...
